

[Dactinomycin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01DA01](#)

EMLc

Indication

Rhabdomyosarcoma primary site ICD11 code: [2C25.Z](#)

INN

Dactinomycin

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 500 µg in vial powder for injection

EML status history

First added in 1984 ([TRS 722](#))

Changed in 2015 ([TRS 994](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Dactinomycin](#)

[DrugBank](#)

[Dactinomycin](#)

Summary of evidence and Expert Committee recommendations



In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML and EMLc for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.